Diagnostic value of circulating lncRNA ANRIL and its correlation with coronary artery disease parameters

Hu, Yao; Hu, Jing

doi:10.1590/1414-431x20198309

Cited by 30 publications

(23 citation statements)

References 19 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…long non-coding rnas (lncrnas) are a category of noncoding rnas (ncrnas) that have almost no protein coding function and a length of >200 nucleotides (9). an intriguing lncrna, lnc-antisense non-coding rna in the inK4 locus (lnc-ANRIL), has been identified in a number of diseases with a pathology related to inflammation and neurodysfunction, including diabetic retinopathy, coronary artery disease and spinal cord injury (10)(11)(12)(13). These findings indicate that lnc-ANRIL may be a genetic factor participating in the regulation of inflammation and neurodysfunction; thus, it was hypothesized that lnc-anril may also mediate neurodegeneration and inflammation in AD.…”

Section: Introductionmentioning

confidence: 99%

Long non-coding RNA ANRIL knockdown suppresses apoptosis and pro-inflammatory cytokines while enhancing neurite outgrowth via binding microRNA-125a in a cellular model of Alzheimer's disease

Zhou

Qiu

et al. 2020

Mol Med Rep

View full text Add to dashboard Cite

The present study aimed to investigate the effect of the long non-coding rna antisense non-coding rna in the inK4 locus (lnc-anril) knockdown on apoptosis, neurite outgrowth and inflammation based on a PC12 cellular alzheimer's disease (ad) model. a cellular ad model was constructed by treating nerve growth factor stimulated PC12 cells with amyloid β (aβ) 1-42 and then control knockdown plasmid and lnc-anril knockdown plasmid were transfected in the Pc12 cellular ad model as the Kd-negative control (nc) group or the ad-anril group respectively. Apoptosis, neurite outgrowth, pro-inflammatory cytokines and microrna (mir)-125a were assessed. rescue experiments were conducted by transfecting lnc-ANRIL knockdown plasmid and lnc-anril knockdown plasmid and mir-125a inhibitor in the PC12 cellular AD model as the KD-ANRIL group or Kd-anril + Kd-mir-125a group respectively. Following transfection, cell apoptosis deccreased while neurite outgrowth increased in the Kd-anril group compared with the Kd-nc group (all P<0.01). concerning inf lammation, tumor necrosis factor-α (TnF-α) and interleukin (il)-1β, il-6 and il-17 were decreased in the Kd-anril group compared with the Kd-nc group (all P<0.01). miR-125a was negatively regulated by lnc-ANRIL and therefore rescue experiments were subsequently conducted. in the rescue experiments, cell apoptosis was increased while total neurite outgrowth was inhibited in the Kd-anril + Kd-mir-125a group compared with the Kd-anril group (all P<0.01), and TnF-α, il-1β, il-6 and il-17 were increased in the Kd-anril + Kd-mir-125a group compared with the Kd-anril group (all P<0.01). a luciferase reporter assay demonstrated that lnc-ANRIL directly bound miR-125a. lnc-ANRIL knockdown suppressed cell apoptosis and inflammation while promoting neurite outgrowth via binding of miR-125a in AD.

show abstract

Section: Introductionmentioning

confidence: 99%

Long non-coding RNA ANRIL knockdown suppresses apoptosis and pro-inflammatory cytokines while enhancing neurite outgrowth via binding microRNA-125a in a cellular model of Alzheimer's disease

Zhou

Qiu

et al. 2020

Mol Med Rep

View full text Add to dashboard Cite

show abstract

“…In recent years, the role of long non-coding RNA (LncRNA) in cardiovascular diseases has also been paid more and more attention. For example, research (7) has found that LncRNA ANRIL has high diagnostic value for coronary heart disease. Some research (8) also has verified that LncRNA can be used as a new regulator of cardiac electrophysiology and arrhythmia.…”

Section: Introductionmentioning

confidence: 99%

lncRNA‑MALAT1 expression in patients with coronary atherosclerosis and its predictive value for in‑stent restenosis

Qiu

Sun

2020

Exp Ther Med

View full text Add to dashboard Cite

This study was designed to investigate the long non-coding RNA (lncRNA)-metastasis associated lung adenocarcinoma transcript 1 (MALAT1) expression in patients with coronary atherosclerosis and its predictive value for in-stent restenosis. Ninety-five patients with coronary heart disease who came to our hospital for treatment and underwent stent implantation were selected as a research group (RG), and 95 volunteers undergoing physical examination who did not suffer from coronary heart disease during the same period were selected as a control group (CG). MALAT1 of subjects in both groups before and after treatment were detected by RT-qPCR, and N-terminal pro-brain natriuretic peptide (NT-proBNP), high sensitivity C-reactive protein (hs-CRP), lactate dehydrogenase (LDH), and creatine kinase isoenzyme (CK-MB) of them in the RG before treatment were detected. The level was evaluated and detected, and its correlation with MALAT1 was analyzed. Then, the predictive value of MALAT1 for in-stent restenosis in patients with coronary heart disease was analyzed. MALAT1 expression in patients with coronary heart disease was higher than that of normal subjects (P<0.05); after treatment, the expression levels of MALAT1, NT-proBNP, hs-CRP, LDH, and CK-MB in the serum of patients were significantly lower than those before treatment (P<0.05); MALAT1 expression was positively correlated with the expression levels of NT-proBNP, hs-CRP, LDH, and CK-MB (P<0.05). Receiver operating characteristic of MALAT1 for predicting in-stent restenosis in patients with coronary heart disease was over 0.8; the number of lesions, MALAT1, diabetes, NT-proBNP and hs-CRP were independent risk factors for in-stent restenosis. MALAT1 is highly expressed in the serum of patients with coronary heart disease, and it has high value in its diagnosis and the prediction of in-stent restenosis. It is also an independent risk factor for in-stent restenosis in patients with coronary heart disease.

show abstract

“…Previous studies showed that ANRIL was highly expressed in endothelial and may be involved in the thrombogenesis 21,22 . Moreover, increased ANRIL has long been investigated as a potential marker in the plaque of atherosclerosis patients 23 . More and more researchers began to investigate the role of ANRIL in cardiovascular diseases; however, there are little reports about the clinical and prognostic significance of ANRIL in AF with ischemic stroke.…”

Section: Discussionmentioning

confidence: 99%

The correlation of serum long non‐coding RNA ANRIL with risk factors, functional outcome, and prognosis in atrial fibrillation patients with ischemic stroke

Zeng

Jin

2020

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background This study aimed to evaluate the predictive value of long non‐coding RNA (lncRNA) antisense non‐coding RNA in the INK4 locus (ANRIL) for atrial fibrillation (AF) patients with ischemic stroke and investigate its correlation with risk factors, functional outcome, and prognosis. Methods A total of 386 consecutive AF patients were recruited. AF patients were followed up for 24‐48 months by outpatient follow‐up, telephone follow‐up, and medical record. The time of ischemic stroke in patients with AF was recorded, and follow‐up was continued for 6 months. LncRNA ANRIL expression from serum was detected by quantitative real‐time polymerase chain reaction (qRT‐PCR). Results Compared with the AF with ischemic stroke group (14.3 ± 2.3), patients in the AF without ischemic stroke group (11.9 ± 1.8) had significantly lower serum lncRNA ANRIL levels ( P < .05). The sensitivity and specificity of lncRNA ANRIL for identifying AF with ischemic stroke were 76.6% and 81.4%, respectively. Spearman correlation analysis results shown that lncRNA ANRIL was significantly correlated with the NIHSS score ( r Spearman = .490, P < .001) and the mRS score ( r Spearman = .466, P < .001). Compared with the lncRNA ANRIL high‐expression group, the recurrence‐free survival (RFS) of the lncRNA ANRIL low‐expression group was significantly higher ( χ 2 = 11.009, log‐rank P < .001). Cox proportional regression model analysis indicated that the serum lncRNA ANRIL level ( P = .004), NIHSS score ( P = .001), infarct volume ( P = .035), and smoking ( P < .001) were the risk factors for AF with ischemic stroke. Conclusion Serum lncRNA ANRIL exerts a good predictive value for AF with ischemic stroke, and its increased expression is correlated with worse RFS for patients.

show abstract

Diagnostic value of circulating lncRNA ANRIL and its correlation with coronary artery disease parameters

Cited by 30 publications

References 19 publications

Long non-coding RNA ANRIL knockdown suppresses apoptosis and pro-inflammatory cytokines while enhancing neurite outgrowth via binding microRNA-125a in a cellular model of Alzheimer's disease

Long non-coding RNA ANRIL knockdown suppresses apoptosis and pro-inflammatory cytokines while enhancing neurite outgrowth via binding microRNA-125a in a cellular model of Alzheimer's disease

lncRNA‑MALAT1 expression in patients with coronary atherosclerosis and its predictive value for in‑stent restenosis

The correlation of serum long non‐coding RNA ANRIL with risk factors, functional outcome, and prognosis in atrial fibrillation patients with ischemic stroke

Contact Info

Product

Resources

About